The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting

Alice B Gottlieb; April W Armstrong; Robin Christensen; Amit Garg; Kristina Callis Duffin; Wolf-Henning Boehncke; Joseph F Merola; Dafna D Gladman; Philip J Mease; Robert A Swerlick; Cheryl F Rosen; April Abernethy

doi:10.3899/jrheum.140176

The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting

J Rheumatol. 2014 Jun;41(6):1227-9. doi: 10.3899/jrheum.140176.

Affiliation

¹ From the Tufts Medical Center, Boston, Massachusetts; Department of Dermatology, University of Colorado, Denver, Colorado, USA; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; Department of Dermatology, Hofstra North Shore LIJ School of Medicine, Hempstead, New York; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Department of Dermatology, Geneva University Hospital, Geneva, Switzerland; Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA; University of Toronto, Toronto Western Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Seattle Rheumatology Associates, Rheumatology Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, Emory University, Atlanta, Georgia, USA; Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada; National Psoriasis Foundation, Portland, Oregon, USA.A.B. Gottlieb, MD, PhD, Tufts Medical Center; A.W. Armstrong, MD, MPH, Department of Dermatology, University of Colorado; R. Christensen, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; A. Garg, MD, Department of Dermatology, Hofstra North Shore LIJ School of Medicine; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah; W-H. Boehncke, MD, Department of Dermatology, Geneva University Hospital; J.F. Merola, MD, Harvard Medical School, Brigham and Women's Hospital; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto; Senior Scientist, Toronto Western Research Institute; Director, Psoriatic Arthritis Program, University Health Network; P.J. Mease, MD, Seattle Rheumatology Associates, Director, Rheumatology Research, Swedish Medical Center, Clinical Professor, Univ

PMID: 24882858
DOI: 10.3899/jrheum.140176

Abstract

In the United States, access to care is the number one issue facing our patients with dermatological conditions. In part, this is because we do not have outcome measures that are useful in clinical practice and available in databases where payers and governmental agencies can compare the performance of physicians and treatments. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials and subsequently in clinical practice. The International Dermatology Outcome Measures group includes all willing stakeholders: patients, physicians, payers, and pharmaceutical scientists. As reported herein, the group's goal is to develop outcome measures in dermatology that address the needs of all involved.

Keywords: INTERNATIONAL DERMATOLOGY OUTCOME MEASURES; NATIONAL PSORIASIS FOUNDATION; OMERACT; OUTCOME MEASURES; PSORIASIS.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Dermatology*
Health Services Accessibility*
Humans
Outcome Assessment, Health Care*
Psoriasis / therapy*
Severity of Illness Index
United States